This study is checking if a new drug mix called daraxonrasib and zoldonrasib works better than regular chemotherapy for adults with a specific type of pancreatic cancer. Pancreatic adenocarcinoma is a cancer in the pancreas, and "metastatic" means it has spread. KRAS G12D mutation is a change in the cancer cells' genes.

Participants in the study will be put into one of two groups: one group will receive the new drug combination (daraxonrasib + zoldonrasib), and the other will get the standard chemotherapy drugs, gemcitabine and nab-paclitaxel.

• The study is global and open-label, meaning both doctors and patients know which treatment they receive.
• Participants must be at least 18 years old and meet specific health criteria, like confirmed pancreatic cancer and good organ function.
• There are certain health conditions and previous treatments that disqualify a person from participating.

Participants will be monitored to see if the new treatment helps them live longer without the cancer getting worse. It's important to talk to a doctor to see if joining the study is a good idea.